UNSPSC 51142573: Tropatepine

This classification denotes a tropane and dibenzothiepin with the molecular formula C22H23NS, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C27HY5RFU5, chemically known as 8-azabicyclo(3.2.1)octane, 3-dibenzo(b,e)thiepin-11(6h)-ylidene-8-methyl- but more generally known as tropatepine, which bears U.S. NIH Compound Identifier 72148. European Medicines Agency schedules Tropatepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11340MIG.

World Health Organization schedules tropatepine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. TROPATEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51142573 Tropatepine is a Commodity code for pharmaceutical products, though recent state and local solicitations under this code show limited activity directly aligned with tropatepine itself. The recent opportunities instead reflect broader state and local procurement of naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. State and local buyers under related pharmaceutical codes include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, and the Texas Health and Human Services Commission represent the primary issuers in the recent record; Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP) administers a large multi-jurisdiction pharmaceutical procurement spanning participating state and local government facilities in Minnesota and Oregon. The scope of work covers supply of finished pharmaceutical products with specific National Drug Codes, compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and distribution through authorized wholesalers with quarterly or ongoing deliveries to designated state and local health facilities.

Recent opportunities span Florida, Texas, and the Minnesota-Oregon corridor through MMCAP. Seminole County issued an IFB (IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2026, and an initial two-year contract term plus one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 exploring vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, indicating early-stage market research prior to formal procurement. MMCAP issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and operational compliance, and an effective date of July 1, 2026. Vendors in all three opportunities must meet federal compliance requirements, maintain specific insurance coverages, and provide detailed product information including NDC codes and packaging specifications.